Albireo to participate in 2022 wedbush pacgrow healthcare conference

Boston, aug. 03, 2022 (globe newswire) -- albireo pharma, inc. (nasdaq: albo), a rare liver disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced participation in the 2022 wedbush pacgrow healthcare conference august 9-10, 2022. ron cooper, president and chief executive officer of albireo, will be presenting on august 9, 2022. a replay of the webcast will be available on-demand on the albireo investors page ir.albireopharma.com. ron and simon harford, chief financial officer, will host meetings with investors.
ALBO Ratings Summary
ALBO Quant Ranking